In a recent analysis by ETF Channel, Lam Research Corp (LRCX) has ascended to the 59th spot in analyst recommendations for S&P 500 components, surpassing Regeneron Pharmaceuticals, Inc. (REGN). This ranking shift reflects a notable change in market sentiment towards these companies.
As of midday Thursday, Lam Research is trading approximately 2.5% higher, while Regeneron has decreased by about 0.7%. This performance variance highlights the competitive landscape between the two firms in the technology and pharmaceuticals sectors.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
